Avita Medical, Inc. Common Stock (RCEL)

AVITA Medical announced Cary Vance as Interim CEO, replacing Jim Corbett. The company expects Q3 2025 revenue of approximately $17 million and is seeking a permanent CEO through an executive search.

Avita Medical reported Q2 2025 earnings with commercial revenue rising 21% to $18.4 million, but missing consensus estimates due to Medicare reimbursement delays. The company reduced its full-year revenue guidance and delayed profitability expectations.

AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish ...

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.